Immune thrombocytopenia
Not recruitingA Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment
A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment
- Disease:Immune thrombocytopenia
- Substances:EltrombopagEntecavir+2
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Eltrombopag
- Sponsor:Novartis Pharma AG











